Another trial studied nivolumab in high-risk AML patients in remission but ineligible for allogeneic HSCT, with high risk defined as secondary AML in first CR, high-risk cytogenetics, FLT-3 ITD mutation, presence of minimal residual disease, or second CR or more [73]. The gene discussed is FLT3; the disease is acute myeloid leukemia.